| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LNG |
| Uniprot No | P05067 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-770aa |
| 氨基酸序列 | MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN |
| 预测分子量 | 86,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于“LNG重组蛋白”的虚构参考文献示例(注：实际文献需通过数据库检索确认)：
---
1. **标题**：*Expression and Immunogenicity Analysis of Recombinant LNG Protein from Neisseria gonorrhoeae*
**作者**：Zhang, Y. et al.
**摘要**：研究通过大肠杆菌系统表达了淋球菌(Neisseria gonorrhoeae)的重组LNG蛋白，并验证其作为疫苗候选抗原的免疫原性，动物实验显示可诱导特异性抗体反应。
2. **标题**：*Optimization of LNG-1 Recombinant Protein Production in Pichia pastoris for Vaccine Development*
**作者**：Wang, L. et al.
**摘要**：在毕赤酵母中优化重组LNG-1蛋白的分泌表达工艺，通过发酵条件调控提高产量，为规模化生产疫苗抗原提供技术基础。
3. **标题**：*Structural Insights into LNG Recombinant Protein for Targeted Therapy*
**作者**：Chen, H. et al.
**摘要**：解析了重组LNG蛋白的晶体结构，阐明其与宿主细胞受体的相互作用机制，为设计靶向治疗药物提供结构生物学依据。
4. **标题**：*Diagnostic Potential of Recombinant LNG Fusion Protein in Serological Assays*
**作者**：Kumar, S. et al.
**摘要**：开发基于重组LNG融合蛋白的ELISA检测方法，用于快速诊断特定病原体感染，临床样本验证显示高灵敏度和特异性。
---
**说明**：
- 若“LNG”指特定病原体(如淋球菌)或蛋白，建议在PubMed、Google Scholar等平台以关键词“LNG recombinant protein”+“应用领域(疫苗/诊断)”检索真实文献。
- 实际研究中，重组蛋白命名通常与来源或功能相关(如“HPV L1重组蛋白”)。
建议用户结合具体研究背景进一步筛选文献。
**Background of LNG Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are produced by inserting target gene sequences into host organisms (e.g., bacteria, yeast, or mammalian cells) to express specific proteins. LNG recombinant proteins, often linked to vaccine development or therapeutic applications, exemplify advancements in biotechnology. A notable example is the use of recombinant proteins in vaccines against human papillomavirus (HPV), where the L1 capsid protein self-assembles into virus-like particles (VLPs) to mimic viral structures without infectious genetic material. This approach, utilized in HPV vaccines like Gardasil and Cervarix, enables safe and effective immune activation.
The term "LNG" may refer to specific antigen configurations or proprietary formulations in vaccine design. Recombinant protein technology overcomes limitations of traditional vaccines (e.g., pathogen cultivation risks) by enabling precise antigen design, scalability, and consistency. Beyond vaccines, LNG recombinant proteins are explored for cancer immunotherapy, infectious disease treatments, and diagnostic tools, leveraging their ability to trigger targeted immune responses or bind specific biomarkers.
Production involves optimizing expression systems for protein folding, stability, and post-translational modifications. Challenges include ensuring immunogenicity, avoiding unwanted immune reactions, and achieving cost-effective manufacturing. Recent innovations, such as mRNA-guided protein design or nanoparticle delivery systems, further enhance their therapeutic potential. Overall, LNG recombinant proteins represent a cornerstone of modern biologics, bridging molecular biology and clinical applications to address unmet medical needs.
×
